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ABSTRACT: The recently reported amphiphilic chelate, [Gd(EPTPAC16)(H2O)]
2, forms supramolecular aggregates in
aqueous solution by self-assembly of the monomers with a relaxometrically determined critical micellar concentration
(CMC) of 0.34mM. The effect of sonication on the aggregate size was characterized by dynamic light scattering and
relaxometry, indicating the presence of premicellar aggregates and an overall decrease in aggregate size and polydispersity
upon sonication, slightly below the CMC. {[153Sm](EPTPAC16)(H2O)}
2 radiotracer was evaluated in vivo from g
scintigraphy and biodistribution in Wistar rats. It was found to depend strongly on the sample concentration, below or
above the CMC, and its sonication, in a way that correlates with the effect of the same factors on the size of the aggregates
formed in solution. Below CMC, the very large aggregates of the [153Sm]3þ-labeled chelate were persistently and mainly
taken up by the lungs, and also by the macrophage-rich liver and spleen. Sonication of this solution led to loss of the lung
uptake. Above CMC, the metal chelate was mainly taken up by the liver, with very little uptake by the spleen and lungs.
In vivo, dynamic contrast-enhanced (DCE)-MRI evaluation of the micellar [Gd(EPTPAC16)(H2O)]
2 compound in Wistar
rats showed a persistent hepatic positive-contrast effect in T1-weighted images, qualitatively similar to the clinically
established GdIII-based hepatobiliary-selective agents. No enhancement effect was observed in the lungs because of the
scarcity of mobile protons in this organ, despite the scintigraphic evidence of significant lung retention of the
[153Sm]3þ-labeled chelate at concentrations below the CMC. Copyright # 2007 John Wiley & Sons, Ltd.
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INTRODUCTION
Gadolinium(III) chelates have been extensively used as
paramagnetic contrast agents (CAs) for MRI (1–6). The
first generation of MRI CAs, including [Gd(DOTA)
(H2O)]
 (DOTA¼ 1,4,7,10-tetra-azacyclododecane-1,4,
7,10-tetra-acetate) and [Gd(DTPA)(H2O)]
2 (DTPA¼
diethylenetriamine penta-acetate) among others, are
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extracellular agents, distributing non-specifically through-
out the plasma and interstitial spaces and being rapidly
excreted via the kidneys (7). In the emerging field of
cellular and molecular imaging using MRI, more efficient
(higher relaxivity) and biospecific CAs are required to
deliver as many GdIII-containing species as possible to the
cellular targets of interest and therefore attain sufficiently
high contrast to obtain their images (8).
At the magnetic field strengths currently used in MRI
(0.5–3.0 T, 21.29–127.73MHz for protons), the aptitude
of GdIII chelates to enhance the longitudinal water proton
relaxation rate per mmol of CA (relaxivity) is mainly
determined by the inner-sphere water-exchange rate (kex)
and the rotational correlation time of the chelate (tR)
(2–4). The charge of the complex and the steric crowding
in the inner coordination sphere have been shown to be
the main factors affecting water exchange in GdIII
poly(aminocarboxylate) complexes (9,10). Chelators that
ensure optimal fast water exchange on the GdIII complex
have been developed by inducing steric crowding around
the water-binding site, by elongation of the amine
backbone or by elongation of a pendant carboxylate arm
of the ligand, for both linear (DTPA-type) and macro-
cyclic (DOTA-type) chelates (11–13), or by replacing a
pendant carboxylate by a phosphonate group (14). This
facilitates the removal of the water molecule by a dis-
sociative mechanism, accelerating the exchange. Several
approaches have been devised to increase tR through
covalent attachment of GdIII chelates to slowly tumbling
macromolecules (2–5), such as carbohydrates (15–17),
proteins (18) and dendrimers (19,20). The formation of
host–guest non-covalent interactions between GdIII che-
lates and macromolecules (5,21,22) or b-cyclodextrin
oligomers (23) has also been explored. An alternativeway
to increase tR is through self-assembly of amphiphilic
GdIII chelates or through inclusion of lipophilic GdIII
chelates in liposomes or other lipid-based systems.
However, when the water-exchange rate in the GdIII
inner sphere is not optimized in these macromolecular
agents, their proton relaxivity is still seriously limited.
Lipid-based nanoparticles, such as micelles and
liposomes, have been used as colloidal drug carrier
vehicles (24–26) and as contrast-enhanced MRI and
molecular imaging agents (27,28). Liposomal MRI CAs
include, among other types, liposomes entrapping
hydrophilic paramagnetic agents in the aqueous lumen
or carrying amphiphilic agents on the liposomal surface
with the hydrophobic part non-covalently anchored in the
lipid bilayer (27,28). In addition to the increased
relaxivities, colloidal CAs made up of GdIII-containing
supramolecular assemblies can be efficiently taken up by
macrophage-rich tissue undergoing endocytosis/phago-
cytosis (liver and spleen) (29). This provides an efficient
way of delivering therapeutic and diagnostic agents to
cells with the aid of colloidal-drug-carrier systems.
However, the fast sequestration of intravenously injected
colloidal-drug carriers from the blood by Kupffer cells
(liver/spleen resident macrophages) is a drawback for
efficient targeting of drug carriers or diagnostic agents to
a specific macrophage population or to non-macrophage
sites. As a consequence, there has been increasing interest
in the design of colloidal-drug-carrier systems that, by
avoiding rapid recognition by Kupffer cells, remain in the
blood for long periods. Such carriers have applications in
vascular drug delivery and release and site-specific
targeting (24). Long-circulating colloidal systems with
entrapped radiopharmaceuticals or CAs have been
successful in blood-pool imaging (20–32). Micelles pre-
pared from poly(ethylene glycol)–lipid conjugates have
been shown to be useful in the delivery of therapeutic or
diagnostic agents to areas of myocardial infarction (33).
Micelles may themselves be made up of amphiphilic
ions or molecules or can originate separately and act as
vehicles to transport poorly soluble compounds (mixed
micelles). The effectiveness of micelles as delivery agents
depends, among other factors, on their critical micellar
concentration (CMC), because, on intravenous injection,
micelles are often diluted to less than their CMC.
Several gadolinium-based micelles have been relax-
ometrically characterized and reported in the literature:
linear copolymers of GdIII–DTPA conjugates linked by
a,v-alkyldiamides with a varying number of methylene
groups separating the amide function (34,35); GdIII–
DTPA-bisamide-(CH2)n copolymers (n¼ 6, 10 or 12)
(36); GdIII–DOTA derivatives bearing alkyl or mono-
amide-alkyl aliphatic side chains (C10–C18) (37,38); Gd
III
chelates of 1,4,7-tris(carboxymethyl)-10-(2-hydroxyl-
alkyl)-1,4,7,10-tetra-azacyclododecane ligands of vary-
ing alkyl chain length (39); GdIII chelates of C8-DOTP
and C11-DOTP, two fatty acid analogues of DOTP
[1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetrakis(met-
hylenephosphinate)] (40,41); GdIII–3,6,9,15-tetra-aza-
bicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triace-
tate (42); gadofluorine 8 with a LnIII–DO3A monoamide
hydrophilic head (Ln¼Gd or Y) (43).
The formulation for the preparation of stable mixed
micelles based on gadolinium chelates usually includes
an amphiphilic GdIII chelate, phospholipid(s) and a
surfactant. These micelles should meet the criteria of high
contrast efficiency (high relaxivity), small particle size,
high loading, good stability and easy production. Several
mixed systems have been relaxometrically and/or phar-
macologically studied: mixed micelles based on GdIII–
DTPA derivatives (44); GdIII–HHD-DO3A-cholesterol
(HHD¼ hydroxyhexadecyl) (45,46); mixed micelles of
the GdIII–DTPA–cholesterol conjugate (47); GdIII–DTPA
monoamide and bisamide derivatives with alkyl chains
(C12, C14, C16 or C18) (48,49). Target-specific mixed
micelles based on GdIII–C18DTPAGlu/C18CCK8 have
also been reported; their effectiveness is due to the
presence of the bioactive peptide CCK8, which acts as
targeting vector for cholecystokinin (CCK) receptors
localized in the cell membrane, which are overexpressed
in many tumors (50).
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We have previously reported the synthesis and charac-
terization of the GdIII complex of the chelator, H5EPTPAC16
[(hydroxymethylhexadecanoyl ester) ethylenepropylene
triaminepenta-acetic acid] (Fig. 1) (51). This chelate
displays an increased water-exchange rate (kex) resulting
from steric compression around the water-binding site.
The attachment of a palmitic ester unit to the ethylenedia-
mine bridge yields an amphiphilic conjugate which forms
supramolecular aggregates, possibly micelles, in aqueous
solution, with a calculated CMC of 0.34mM at 258C (51).
A global analysis of the variable-temperature, multiple-
field 17O NMR, electron paramagnetic resonance and
1H NMR dispersion data allowed determination of the
parameters governing the relaxivity of [Gd(EPTPAC16)
(H2O)]
2. The micelles formed in aqueous solution
showed considerable internal flexibility, leading to a
limited increase in proton relaxivity (51).
In the present work, we studied how the self-assembly
of the amphiphilic monomer metal chelates into
supramolecular aggregates dramatically influences their
in vivo behavior and determines their performance as
potential imaging agents. We also report the evaluation of
the [153Sm]3þ-labeled compound in Wistar rats through
pharmacokinetic studies involving in vivo dynamic
g-scintigraphy and biodistribution. The effects of concen-
tration and preparationmethod (with and without sonication)
of the radiotracer {[153Sm](EPTPAC16) (H2O)}
2 solu-
tion on its biodistribution were correlated with the size
distribution of the aggregates, determined by dynamic
light scattering (DLS). The influence of sonication on
[Ln(EPTPAC16)(H2O)]
2 in water was monitored by
NMR and relaxometry. An in vivo MRI study of the
contrast effects and pharmacokinetics of the micellar
[Gd(EPTPAC16)(H2O)]
2 complex in Wistar rats is also
reported and compared with a typical commercial,
low-molecular-mass CA, GdDTPA (Magnevist1).
EXPERIMENTAL
H5EPTPAC16 was synthesized as described previously
(51).
Preparation of LnIII–EPTPA complexes
The general procedurewas dissolution of H5EPTPAC16 in
distilled water and addition of a molar equivalent of
LnCl3 solution (Ln¼Eu, Gd). The pH was adjusted to
5.5 with aqueous KOH (0.1M). The solution was stirred
at room temperature for 1 h and then adjusted to pH 7.0
with aqueous KOH (0.1M). The solution was concen-
trated at reduced pressure giving rise to a white solid.
For the DLS experiments, 0.2mM and 2mM solu-
tions were prepared by dissolving the corresponding
[Gd(EPTPAC16)(H2O)]
2 complex in 150mM MES
[2-(N-morpholino)ethanesulfonic acid hydrate, 99.5%]
buffer, pH 6.4. Samples were sonicated using a Bandelin
Sonorex RK 106S sonicator (P¼ 200W, y¼ 35MHz).
Aqueous solutions of [Gd(EPTPAC16)(H2O)]
2 were
prepared for the relaxometric experiments, whereas
the NMR experiments used D2O solutions of
[Eu(EPTPAC16)(H2O)]
2.
NMR measurements
1H NMR spectra were recorded in D2O (99.99%
2H) on
Varian Unity Plus 300 and Unity 500 NMR spec-
trometers, operating at 299.938MHz and 499.80MHz,
respectively. Chemical shifts (d) are given in ppm relative
to TSP as internal reference (1H, d 0.0).
Relaxometric measurements
Water 1H relaxivity measurements were performed on a
Bruker Minispec mq60 (60MHz) at 258C and 378C. The
temperature was measured by a substitution technique.
Longitudinal relaxation rates were measured at four
different concentrations, two below (0.1 and 0.2mM) and
two above (2.0 and 4.0mM) the CMC before and after 2,
4 and 20min of sonication.
DLS measurements
These were performed on a Coulter1 N4 Plus Submicron
Particle Sizer. The N4 Plus contains a 10mW He–Ne
Figure 1. Structure of the metal chelator, H5EPTPA. The
relevant structural features (highlighted) are: substitution of
an ethylenediamine bridge by a propylenediamine bridge
resulting in stereochemical compression around the water-
binding site in the Gd3þ complex, and a pendant hydro-
xymethyl-linked palmitic acid ester moiety rendering the
molecule amphiphilic.
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laser which emits monochromatic polarized light with a
wavelength of 632.8 nm. The electric field polarization is
perpendicular to the plane formed by the incident and
detected rays (vertical polarization). The particle size is
calculated from the measurement of the sample diffusion
coefficient by photon correlation spectroscopy. The N4
Plus is controlled by PC-based software which operates in
the Microsoft Windows environment. Before data
acquisition, the sample was allowed to equilibrate for
2min. All the measurements were performed at an angle
of 908 and at 208C. The data acquired were analysed by
unimodal analysis, which yields the mean intensity-
weighted particle size and standard deviation. The mean
intensity-weighted particle size was determined for each
solution concentration over time, without and with 2min
of sonication of the solution. Multimodal DLS analysis
was performed with a Zetasizer Nano ZS instrument
(Malvern Instruments Ltd, Malvern, UK) equipped with a
4mW He–Ne laser at 633 nm with backscattering
detection at 1738.
Reagents for g imaging and
biodistribution studies
153SmCl3 was produced at the Instituto Tecnolo´gico e
Nuclear, Lisbon, Portugal by Dr Maria dos Anjos Neves,
with a specific radioactivity of >5GBq/mg. For this
purpose, 153Sm2O3 was prepared from a 98%
152Sm-
enriched Sm2O3 target, sealed into a quartz vial and
welded into an aluminum can, by neutron irradiation
using a thermal flux of 2.3 1013 n/cm2  s. After irradia-
tion, the sample was opened, dissolved in 1MHCl, and
the final 153SmCl3 solution was brought to a stock
concentration of 1.9 103M.
Radiotracer preparation
Stock solutions of H5EPTPAC16 were prepared in
150mM MES buffer, pH 6.4, and mixed with 153SmCl3.
The solutions were left stirring at room temperature for
1 h. Solutions with different concentrations of the
radiotracer, 0.2mM (below CMC) and 2mM (above
CMC) [CMC¼ 0.34mM, determined by relaxometry
(51)], were prepared for biodistribution and g imaging
experiments. The solution of 2mM concentration of
radiotracer was prepared by adding to a 0.2mM solution
of the {[153Sm](EPTPAC16)(H2O)}
2 radiotracer the appro-
priate amount of non-radioactive {[152Sm](EPTPAC16)
(H2O)}
2 complex.
In vivo g imaging
A g camera–computer system (GE 400 GenieAcq;
General Electric, Milwaukee, WI, USA) was used for
acquisition and preprocessing. Data processing and
display were performed on a PC using homemade
software developed for the IDL 5.2 computer tool. Awell
counter (DPC-gamma C12, Los Angeles, CA, USA) with
a Compaq DeskPro compatible computer was used for
radioactivity counting in the biodistribution studies.
g images and biological distribution of [153Sm]3þ
complexes were determined using 200–250 g Wistar rats.
All animal studies were carried out in compliance with
procedures approved by the appropriate institutional
review committees. Conscious rats were allowed free
access to food and water ad libitum. Groups of four
animals (one group for each concentration of the
radiotracer with and without sonication) were anesthe-
tized with 50mg/ml ketamine/2.5% chlorpromazine
(10:3, v/v) and injected into the femoral vein with
200mCi of the [153Sm]3þ complex immediately after
the solution had been prepared. Two different injected
dose concentrations were studied (0.2mM and 2mM) as
well as the effect of 2min of sonication on the g
scintigraphic image. The animals were then positioned in
dorsal decubitus over the detector. Image acquisition was
initiated immediately before radiotracer injection.
Sequences of 180 images (of 10 s each) were acquired
to 64 64 matrices. In addition, static data were acquired
24 h after the radiotracer injection.
Images were subsequently processed using an IDL-
based program (Interactive Data Language, Research
Systems, Boulder, CO, USA). For analysis of the
transport of radiotracer over time, three regions of
interest (ROIs) were drawn on the image files,
corresponding to the thorax, liver and left kidney. From
these regions, time–radioactivity curves were obtained.
Biodistribution studies
Groups of four animals were injected in the tail vein with
100mCi of the [153Sm]3þ tracer (at the concentrations
and conditions stated in the scintigraphic imaging
section) and killed 1 h later. The major organs were
excised and weighed, and tissue radioactivity was
measured in a g well counter. Similar biodistribution
studies were also performed with the animals referred to
in the previous section killed at 24 h.
MRI
Sample formulation/preparation of [Gd(EPTPAC16)
(H2O)]
2 for MRI. The ligand, H5EPTPAC16 (147.4mg;
0.218mmol), was dissolved in distilled water. To this
solution was added dropwise an aqueous solution of
Gd(NO3)3.6H2O (90.0mg; 0.199mmol). The pH was
kept at 5.5–6.0 by the addition of NaOH (aqueous
solution, 0.1M). The reaction mixture was left stirring for
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1 h. The solution was adjusted to pH 7.0 with NaOH
(aqueous solution, 0.1M), filtered (Filtropur S filters,
0.2mm), and concentrated under reduced pressure. The
absence of free metal was confirmed by the xylenol
orange test.
To remove the salts (NaNO3) produced during the
synthesis of the [Gd(EPTPAC16)(H2O)]
2 complex, a
sample was purified by silica-gel 100 C8 reverse-phase
chromatography with gradient elution, 100% water!
100% ethanol. The relevant fractions, identified by
reverse-phase C18 thin-layer chromatography and con-
ductivity measurement, were pooled, filtered (Filtropur S
filters, 0.2mm), and concentrated under reduced pressure
to give the salt-free complex, probably [Gd(EPTPA-
C16)(H2O)]Na/K2, as a vitreous solid.
In vivo MRI studies. The experimental protocols
performed were approved by the appropriate institutional
review committees and followed the guidelines of their
responsible governmental agency. The MRI experiments
were all performed on a Bruker Pharmascan platform
(Bruker Medical Gmbh, Ettlingen, Germany) using a
7.0 T horizontal-bore superconducting magnet, equipped
with a 1H-selective 60mm birdcage resonator and a
Bruker gradient insert with 90mm diameter (maximum
intensity 300mT/m). Data were acquired using a
Hewlett-Packard console running Paravision software
(Bruker Medical) in a Linux environment.
All MRI examinations were carried out on male Wistar
rats (n¼ 4, 250–260 g body weight) anesthetized initially
by inhalation in an induction box with O2 (1 liter/min)
containing 3% isoflurane, and maintained during the
experiment using a mask and 1–2% isoflurane in O2.
Animals were taped down into a holder to minimize
breathing-related motion, and then placed in a heated
probe, which kept the core body temperature at 378C,
monitored by a rectal probe. The physiological state of the
animal was monitored throughout the experiment with a
Biotrig physiological monitor (Bruker Medical), using
the respiratory rate and body temperature. Solutions of
[Gd(EPTPAC16)(H2O)]
2 and [Gd(DTPA)(H2O)]
2
(Magnevist1; Schering, Berlin, Germany; 100mM) were
prepared in distilled water, and the pH was adjusted to
7.2. The solutions were injected into the catheterized tail
vein as a bolus of 200mL in 20 s (0.2mmol Gd/kg body
weight) using an infusion pump (Panlab, Barcelona,
Spain).
T1-weighted spin-echo anatomical images (TR¼
200ms; TE¼ 11.7ms; field of view¼ 6 6 cm; acqui-
sition matrix¼ 256 256; number of averages¼ 2; slice
thickness¼ 2mm; two packages of four slices each,
centered on the liver and on the kidneys) were acquired in
axial orientation. Baseline images were acquired before
the administration of our CA, [Gd(EPTPAC16)(H2O)]
2.
After injection, regional CA uptake was assessed by
acquiring sequential images for 1 h (50 images).
MRI data processing. Data were analyzed with
software written in-house using IDL. With the aim of
comparing the pharmacokinetics obtained from different
animals, the data were normalized by calculating the
relative enhancement (RE):
RE ¼ ðI  I0Þ
I0
 100
where I is the signal intensity at any given time after CA
injection, and I0 is the intensity before injection.
Pharmacokinetics were analyzed by calculating the
average enhancements within different ROIs in each
one of the following regions: liver, kidney medulla,
kidney cortex, vena cava and muscle.
RESULTS AND DISCUSSION
DLS studies
The effects of concentration and sonication of aqueous
[Gd(EPTPAC16)(H2O)]
2 solutions on the average
particle size and polydispersity index (PI) were studied
by DLS at 208C (Fig. 2). We assumed that the CMC does
not change between 258C (51) and 208C, as observed
for [Gd(DOTAC14)(H2O)] between 58C and 258C (38).
For [Gd(EPTPAC16)(H2O)]
2 concentrations (0.2mM)
below the CMC and without sonication, the mean
intensity-weighted particle size was above the working
range of the instrument (<3000 nm). After 2min of
sonication, it decreased to500 nm, and a heterogeneous
population of aggregates was present (PI 1.0). The
duration of the sonication, 2 or 4min, did not substantially
affect either the mean intensity-weighted particle size or
the PI (not shown). The aggregates formed on sonication
Figure 2. DLS studies on the effect of concentration and
sonication of the [Gd(EPTPAC16)(H2O)]
2 solution on the
average particle size (mean SD) and population distri-
bution, as measured by PI.
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remained stable for at least 4 h with regard to size and
polydispersity (Fig. 2). For [Gd(EPTPAC16)(H2O)]
2
solutions of concentration 2mM (above the CMC), the
mean intensity-weighted particle size (450 nm) was the
same before and after 2min of sonication. However,
sonication reduced the heterogeneity of the aggregates, as
indicated by a decrease in PI from 1.5 to 1.0.
Furthermore, both the mean intensity-weighted particle
size and the PI decreased over time, reaching values of
300 nm and 0.8, respectively, after 24 h (Fig. 2).
For all concentrations studied, both below and above
the CMC, with and without sonication, a DLSmultimodal
analysis (data not shown) revealed populations of at least
two particle sizes: small particles (diameter<10 nm), and
very large particles (diameter >100 nm) of variable size.
The existence of large particles for concentrations below
the CMC suggests premicellar aggregation. This is in
agreement with a recent study of micelle formation
caused by surfactants in the presence of a reporting dye
using fluorescence correlation spectroscopy that demon-
strated the formation of aggregates in the concentration
range (0.3–1.0)CMC, in increasing number when
approaching the CMC (52). Premicellar aggregation has
been shown to be responsible for anomalies of various
physical parameters (53,54). The large aggregates
probably represent only a very small population below
the CMC. Indeed, the value of the calculated mean
intensity-weighted particle size can be dominated by a
very small population of large particles with high
scattering intensity. This is also in accordance with the
fact that, using relaxometry, we did not observe any
slowly rotating large particles below 0.34mM (CMC
determined by relaxivity measurements) (51). Even if
below the CMC the large aggregates represent a
significant proportion of the population of particles, they
can be extremely flexible, which implies that the proton
relaxivities will not be much increased with regard to the
monomer state.
In conclusion, at a concentration just below the CMC
(0.2mM in our case), the aggregate morphology and
dynamics can be quite complicated. DLS data at
concentrations lower than 0.2mM would have certainly
been more representative of the ‘non-aggregated’ state.
Effect of sonication on the NMR spectra
and water relaxivity of
[Ln(EPTPAC16)(H2O)]
2Ssolutions
The 1H NMR spectrum of a 10mM D2O solution of
[Eu(EPTPAC16)(H2O)]
2 contains a large number of
high-frequency (e.g. þ25.42, þ17.27, þ14.93, þ13.23,
þ12.33, þ11.67, þ7.96 ppm) and low-frequency (1.58,
2.43,3.04,3.55,4.04,7.45,10.45,10.64ppm)
paramagnetically shifted resonances. This spectrum
(available online as Fig. 1S in Supplementary Material)
is not affected by sonication periods of up to 20min, or
after a subsequent period of 1 day, showing that soni-
cation does not affect the stability and structure of the
complex.
The effect of increasing sonication periods up to 20min
on the 60MHz water 1H longitudinal relaxivity (r1) of
[Gd(EPTPAC16)(H2O)]
2 solutions was studied at differ-
ent concentrations and temperatures (258C and 378C), as
shown in Table 1 for 0.2mM and 2.0mM concentrations.
At the measurement frequency of 60MHz (close to the
maximum of the NMR dispersion curves of the complex
in the micellar form), r1 is mainly determined by the
rotational dynamics of the chelate (51). Hence the
variation in r1 reflects the changes in the rotational
dynamics of the micellar aggregates. As the CMC is
expected to increase by 10% between 258C and 378C
(38), at 378C 0.2mM is still below the CMC (51). Above
the CMC and at any of the temperatures, sonication had
no significant influence on r1. This indicates that
sonication does not affect the average rotational dynamics
of the chelate in the micellar aggregates, as reflected by
the r1 values [more precisely, r1 is determined by the
global (tg) and segmental (tl) rotational correlation times
of the aggregates (51)]. This is in qualitative agreement
with the DLS observation that the mean intensity-
weighted particle size was not affected by sonication at
concentrations above the CMC. Below the CMC, r1
values, which are about half the values above the CMC,
increased with sonication at both temperatures. At 258C,
this increase became larger with sonication time, from 9%
(2–4min) to 14% (20min). At 378C, the r1 increase was
only significant (9%) for 20min of sonication. As
Table 1. Effect of sonication on the 60MHzwater 1H longitudinal relaxivity (r1) of [Gd(EPTPAC16)(H2O)]
2 solutions
at different temperatures and concentrations below and above the CMC. The results are mean SD from three
measurements
r1 (mM
1s1)
258C 378C
0.2mM 2.0mM 0.2mM 2.0mM
No sonication 9.94 0.01 20.55 0.01 6.46 0.01 15.63 0.01
2min sonication 10.94 0.04 20.61 0.01 6.53 0.02 15.63 0.01
4min sonication 10.96 0.02 20.62 0.01 6.53 0.02 15.63 0.01
20min sonication 11.66 0.01 20.63 0.01 7.06 0.04 15.63 0.01
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discussed above, the situation at concentrations just
below the CMC is rather complex with regard to the
formation of preaggregates. Moreover, these structures
are probably very fluxional and may change on soni-
cation. These factors may explain why the significant
decrease in mean intensity-weighted particle size detec-
ted by DLS was not observed in the relaxivities. Con-
centrations significantly lower than 0.2mM would be
much more useful for examining the non-aggregated state.
Studies of [153Sm]3R-labeled EPTPAC16
complex
In vivo g-imaging and biodistribution. Scinti-
graphic images of Wistar rats were obtained as a function
of time after injection of an aqueous solution of 0.2mM
{[153Sm](EPTPAC16)(H2O)}
2 tracer (below CMC).
Fig. 3 compares the images obtained 30min after
injection of the tracer solution without and after 2min
of sonication. Without previous sonication, there is a
marked high uptake/retention of the tracer in the thorax.
Further experiments (dynamic acquisition and biodis-
tribution; see below) revealed that the uptake of the
radiotracer occurred predominantly in the lungs. In sharp
contrast, 2min of sonication of the 0.2mM radiotracer
solution resulted in high liver uptake and virtually no
uptake in the lungs, as demonstrated by dynamic
acquisition and biodistribution (see below).
Time–radioactivity curves for the 0.2mM {[153Sm]
(EPTPAC16)(H2O)}
2 radiotracer without and after 2min
of sonication were obtained in dynamic acquisition
experiments (Fig. 4). The curves were smoothed
and normalized in relation to the maximum radioacti-
vity obtained. The radioactivity of the 0.2mM radiotracer
without sonication increased sharply in the thorax
immediately after the injection, possibly corresponding
to lung uptake/retention of the radiolabeled complex, and
decayed very slowly over the duration of the experiment.
After 30min, the radioactivity remaining in the thorax/
Figure 3. Scintigraphic image at 30min of a Wistar rat
injected with a 0.2mM solution of {[153Sm](EPTPAC16)
(H2O)}
2 (A) without sonication and (B) after 2min of
sonication.
Figure 4. Time–radioactivity curves at various ROIs (liver, kidney and thorax) in Wistar rats
after the injection of a 0.2mM solution of the radiotracer {[153Sm](EPTPAC16)(H2O)}
2 after
2min of sonication (A) and without sonication (B).
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lungs was still 80% of the maximum obtained for this
region. In contrast, the radioactivity in the liver increased
smoothly over the duration of the experiment, and after
30min it was approximately half of that remaining in the
lungs. There was virtually no uptake of radioactivity by
the kidney, consistent with the lipophilic nature of the
radiotracer and its putative hepatobiliary excretion
pathway. Sonication of the radiotracer solution before
injection had a dramatic effect on the dynamic acquisition
curves. The radioactivity in the liver increased sharply
after the injection and reached its highest value after
1min, which can be ascribed to the liver first-pass
uptake of the radiotracer. From there on, the radioactivity
in the liver decayed slowly and smoothly, remaining at
80% after 30min. The radioactivity in the thorax and
kidneys increased immediately after the injection, and
then decayed constantly during the experiment. After
30min, the radioactivity was located mainly in the liver.
The effect of sonication on the biodistribution pattern
of {[153Sm](EPTPAC16)(H2O)}
2 in Wistar rats at 1 and
24 h after injection was studied for concentrations of the
radiotracer below (0.2mM) and above (2mM) the CMC.
Fig. 5 and Table 2 show representative data as a
percentage of injected dose per gram of tissue (%ID/g).
Figure 5. Biodistribution in Wistar rats (percentage of the injected dose/g of organ) of
{[153Sm](EPTPAC16)(H2O)}
2 at 1 h (A) and 24 h (B) after the injection for radiotracer
concentrations of 0.2 and 2mM, with and without sonication. S. Intestine, small intestine;
L. Intestine, large intestine. Values are mean SD.
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Above the CMC, the sonication seems not to have had a
significant effect on the biodistribution pattern. The
radioactivity was located mainly in the liver, with very
low %ID/g found in the blood, kidney, spleen and
heart. These results are consistent with the DLS studies,
which showed that, for concentrations of the radiotracer
above the CMC, it exists as ‘‘small’’ particles (mean
intensity-weighted particle size 450 nm), which are
efficiently taken up by the liver-resident macrophages
(Kupffer cells). Moreover, the DLS studies showed that,
above the CMC, sonication had no significant effect on
the size of aggregates and therefore on the biodistribution
pattern.
Below the CMC and without sonication, there was a
very high uptake and retention of the radiotracer by the
lungs, and significant radioactivity was taken up by the
liver (even higher than its value above the CMC) and
spleen, and to a much lesser extent by the kidney and
blood. These results are consistent with the DLS studies,
which showed the existence of very large micellar aggre-
gates in solution (diameter >3000 nm) in these exper-
imental conditions. These large aggregates were effi-
ciently taken up by resident macrophages in lungs, liver
and spleen (reticuloendothelial system). The high lung
uptake may also be due to entrapment of very large
particles in the narrow lung capillaries. In fact, pulmonary
Table 2. Biodistribution of {[153Sm](EPTPAC16)(H2O)}
2 at 1h and 24h after injection in Wistar rats for radiotracer
concentrations of 0.2 and 2mM without sonication and after sonication for 2min. Results are meanSD from
groups of four animals
Organ
%ID/g (1 h) %ID/g (24 h)
0.2mM 2mM 0.2mM 2mM
No sonication Sonicated No sonication Sonicated No sonication Sonicated No sonication
Blood 0.11 0.07 0.17 0.06 0.042 0.016 0.02 0.01 0.0010 0.0002 0.0016 0.0008 0.00007 0.00003
Kidney 0.13 0.06 0.05 0.02 0.04 0.01 0.03 0.01 0.04 0.01 0.03 0.02 0.004 0.001
Liver 1.04 0.01 0.55 0.02 0.31 0.10 0.46 0.10 0.86 0.11 0.15 0.04 0.03 0.01
Spleen 0.72 0.18 0.15 0.06 0.02 0.01 0.02 0.01 0.76 0.21 0.03 0.01 0.003 0.001
Heart 0.02 0.03 0.06 0.01 0.03 0.01 0.11 0.02 0.012 0.003 0.01 0.01 0.0015 0.0007
Lung 4.32 0.47 0.0090 0.0003 0.0075 0.0002 0.007 0.002 1.68 0.20 0.008 0.005 0.0005 0.0002
Femur — 0.018 0.003 0.03 0.02 0.008 0.002 — 0.03 0.01 0.003 0.001
Figure 6. Comparison of the biodistribution in Wistar rats (percentage of the injected
dose/g of organ) of {[153Sm](EPTPAC16)(H2O)}
2 at 1 h and 24 h after injection for a
radiotracer concentration of 0.2mM without sonication. S. Intestine, small intestine; L.
Intestine, large intestine. Values are mean SD.
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precapillaries are only 8mm in length and 10–15mm in
diameter. Thus, particles with diameters exceeding 10mm
cannot pass through the smallest capillaries and are there-
fore filtered out of the circulation on arrival at these ves-
sels (55). This is the reason for the use of 99mTc-labeled
macro-aggregated albumin to evaluate lung perfusion (56).
The most striking result of the biodistribution studies is
the dramatic effect of sonication on the biodistribution
pattern 1 h after the injection at concentrations of the
radiotracer below the CMC. After sonication, radio-
activity in the lungs virtually disappeared, being mainly
taken up by the liver and to a lesser extent by the spleen.
This biodistribution pattern is virtually equivalent to that
found at radiotracer concentrations above the CMC, the
only difference being some uptake by the spleen. These
results are again consistent with the DLS studies, which
revealed that sonication of the radiotracer solution below
the CMC significantly reduced the size of the particles
(from a diameter of >3000 nm to a mean intensity-
weighted particle size of450 nm). It is also striking that,
with the 0.2mM non-sonicated radiotracer (concentration
below the CMC), there was still very significant
radioactivity in the lungs, liver and spleen after 24 h.
In fact, in the 24 h time span, the liver %ID/g decrease in
non-sonicated radiotracer was 90% at 2mM compared
with only 18% at 0.2mM. In the same time interval,
this value for the 0.2mM non-sonicated radiotracer was
reduced in the lungs by 40% and increased by 6% in
the spleen. This resulted in a total %ID/g ratio (lung/liver
plus spleen) decrease from 2.40 at 1 h to 1.03 at 24 h,
because of the large relative mass of the liver. These
results suggest that the lungs work as a reservoir of
(possibly entrapped) radiotracer, which is slowly released
and taken up by the liver and spleen reticuloendothelial
system (Fig. 6). For 0.2mM sonicated radiotracer, the
%ID/g reduction in the liver and spleen at 24 h was
respectively 73% and 80%.
We have interpreted the biodistribution data for
{[153Sm](EPTPAC16)(H2O)}
2 on the basis of the CMC
determined by relaxometry for the corresponding Gd3þ
complex (51) and correlating the data with the size
distribution of the particles as determined by DLS.
However, the physical state and fate of the radiotracer
once injected is uncertain. On injection, the resulting
dilution, which depends on the volume of the blood
compartment, may reduce the concentration of the
radiotracer to below the CMC, even when injected at
concentrations above the CMC. The situation is even
Figure 7. T1-weighted spin-echo axial MR images of rat
liver before (upper panels) and after (lower panels) the
injection of 0.2mmol/kg [Gd(EPTPAC16)(H2O)]
2 (left) or
[Gd(DTPA)(H2O)]
2 (right).
Figure 8. Representative T1-weighted DCE-MRI series of rat liver (above) and kidney/muscle (below)
axial images before and after the injection of [Gd(EPTPAC16)(H2O)]
2 (0.2mmol/kg). Each pre-contrast
and post-contrast image corresponds to the average of three time points (4min) or 10 time points
(12min), respectively.
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more complex when the concentration of the radiotracer
is already below the CMC when injected. The non-
covalent association of {[153Sm](EPTPAC16)(H2O)}
2
with plasma lipoproteins through anchorage of the fatty
acid chain at their phospholipid monolayer may occur, as
shown for the DTPA–bis(steraylamide) complexes
of Gd3þ and [111In]3þ with high-density lipoproteins
and low-density lipoproteins (57–59). This would allow
their transport and delivery to the liver by receptor-
mediated endocytosis, which would modify the tracer
biodistribution.
MRI
Effect of the Gd chelate on vital functions. The
CA was well tolerated by the mice. Their body tem-
perature remained stable, but respiration rate increased to
120 breaths/min during the first 2–3min after injection,
returning to baseline values within 3min.
MRI in vivo. Series of T1-weighted spin-echo axial
images of the DCE MRI experiments were obtained with
the [Gd(EPTPAC16)(H2O)]
2 complex (dose 0.2mmol/kg
Figure 9. Time course of signal intensity (A) and relative enhancement (B) of several ROIs
during DCE-MRI experiments after the injection of [Gd(EPTPAC16)(H2O)]
2 (0.2mmol/kg).
(A) Data from an individual animal. (B) Mean SE from four animals.
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body weight) and [Gd(DTPA)(H2O)]
2 (dose 0.2mmol/
kg body weight). The [Gd(EPTPAC16) (H2O)]
2 complex
induced a marked increase in the liver, whereas
[Gd(DTPA)(H2O)]
2 had no significant effect (Fig. 7).
A representative series of DCE-MRI data is shown in
Fig. 8; the images correspond to the average of three (pre-
contrast) or 10 (post-contrast) time points. The enhance-
ment in the liver after injection of [Gd(EPTPAC16)
(H2O)]
2 reached a steady state that was maintained until
the end of the experiment. In contrast, the enhancement
observed in the kidneys and muscle was transitory. This is
better illustrated in Fig. 9A, which shows a quantitative
analysis of the same dataset. Each time point corresponds
to the average intensity within the ROIs in the different
organs. For comparison of the results of all the animals
under study, the data were normalized by calculating the
mean relative enhancement of each ROI for the four
animals studied (Fig. 9B). Maximum enhancement was
reached within the first 5min of the injection in all cases.
The initial relative enhancement rose quickly to a
maximum that was higher in the kidney medulla
(280%) and cortex (175%) than in the liver (145%).
However, it rapidly decreased in the kidney to below 90%
after 20min, whereas the enhancement in the liver
remained approximately constant as the predominant
effect throughout the experiment (105% to 100% between
12 and 60min). Fig. 9A also shows that the contrast
enhancement in the abdominal vena cava was also
intensified, although more briefly than in the abdominal
aorta with another colloidal agent, GdDTPA–DeA (60).
CONCLUSIONS
We have recently reported on a new amphiphilic GdIII
complex, [Gd(EPTPAC16)(H2O)]
2, which self-assembles
into supramolecular structures, possibly micelles, with a
CMC of 0.34mM as determined by relaxometry and
surface tension measurements (51). Although its stability
constant could not be determined by potentiometry
because of precipitation at acid pH, its stability should be
similar to that of [Gd(EPTPA)(H2O)]
2 (the EPTPACH2
OH ligand is not linked by an ester group to the long fatty
acid chain; log KGdL¼ 16.7) (61), as the two ligands have
very similar protonation constants (61). This stability is
indeed lower than for the parent unsubstituted chelate,
[Gd(EPTPA)(H2O)]
2 (log KGdL¼ 18.75), for the
substituted [Gd(EPTPA-bz-NO2)(H2O)]
2 (log KGdL¼
19.20) or for [Gd(DTPA)(H2O)]
2 (log KGdL¼ 22.50)
(12). However, in vivo dissociation of the EPTPAC16
complex does not seem to occur, as no accumulation of
radioactive [153Sm]3þ is observed in the rat skeleton (see
data for femur in Table 2). We also believe that the ester
function of the [Ln(EPTPAC16)(H2O)]
2 complexes is
stable in water during sonication, as this treatment did not
cause precipitation of the long-chain fatty acid, had no
effect on the 1H-NMR spectrum of [Eu(EPTPAC16)
(H2O)]
2 {in particular, no new resonances correspond-
ing to the hydrolysis product, [Eu(EPTPA)(H2O)]
2, were
observed (61)} nor on the r1 relaxivity of [Gd(EPTPAC16)
(H2O)]
2 below and above the CMC, which was quite
different from that of GdEPTPACH2OH (61).
Here we present DLS studies on aqueous
[Gd(EPTPAC16)(H2O)]
2 solutions which demonstrate
the existence of aggregates of different sizes both slightly
below and above the CMC. This evidence for premicellar
aggregation is in accordance with previously reported
data for cationic and anionic surfactants (52). As the
CMC is known to depend on the physical method used to
determine it, the value determined by relaxometry, corres-
ponding to a discontinuity in the relaxometric behavior of
the [Gd(EPTPAC16)(H2O)]
2 complex as a function of
the concentration, must be taken as a reasonable
approximation, close to that obtained by classical surface
tension measurements (38).
Slightly below the CMC (0.2mM), the [153Sm]3þ-
labeled chelate was taken up strongly bymacrophage-rich
tissues (spleen, liver and lungs), in accordance with the
existence in solution of very large particles (as deter-
mined by DLS), which are physically trapped in the lungs
(which seem to function as a chelate reservoir) and slowly
released and taken up by the liver and spleen (as shown by
the biodistribution data after 24 h). Above the CMC, the
chelate is mainly taken up by the liver, with very little
uptake by the spleen and lungs. This is consistent with
the presence in solution of smaller particles. Sonication of
the 0.2mM radiotracer solution has a major effect on its
biodistribution: it is mainly taken up by the liver, whereas
its uptake by the lungs virtually ceases. This is consistent
with the reduction in size of the particles after sonication
to one similar to that found in the 2mM solution. This is
not reflected in any significant change in internal
aggregate flexibility and r1 relaxivity, as opposed to the
effect of rigidification of bilayer structures on r1 (62).
At the radiotracer concentrations investigated here,
there are aggregates in solution with different sizes and
structures, in particular at concentrations slightly below
the CMC; this is due to the presence of premicellar
aggregates. The monomodal DLS analysis performed
gives only a simplified view of the very complex popula-
tion dynamics through the weight-averaged particle size
and an index (PI) of population heterogeneity. Further-
more, the effect of the dilution of the metal complex that
occurs on injection on the size and type of aggregates
formed in the blood is difficult to predict. In addition,
the amphiphilic GdIII chelate has the potential to associate
with plasma lipoproteins (57–59) by intercalation of the
lipophilic chain into their phospholipid monolayers.
These facts, taken together, make detailed interpretation
of the in vivo studies difficult. This work highlights the
complexity and subtlety of the in vivo behavior of what
appears to be a simple system. Nonetheless, the rather
simplistic correlation between effect of concentration and
preparation (with sonication and without sonication) of
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the metal chelator on particle size (determined by DLS)
and the biodistribution seems to be significant.
In contrast with liposomal CAs that carry the para-
magnetic amphiphilic GdIII chelate in the lipid bilayer,
which has been reported in various in vivo studies (27,28,
63,64), very few targeted or non-targeted GdIII-based
colloidal CAs have been studied beyond the stage of
basic physicochemical characterization (29,50,63). The
present in vivo DCE-MRI evaluation of the micellar
[Gd(EPTPAC16)(H2O)]
2 compound inWistar rats shows
a persistent hepatic positive-contrast effect in T1-weighted
images, which is qualitatively similar to that of the
clinically-established GdIII-based hepatobiliary agents,
Gd-EOB-DTPA (65) and Gd-BOPTA [where BOPTA is
4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,
8,11-triazatridecan-13-oate] (66), although a comparative
study was not undertaken. No enhancement effect was
seen in the lungs because of the scarcity of mobile protons
in this organ, despite the scintigraphic evidence for
significant lung retention of the [153Sm]3þ-labeled chelate
at concentrations below the CMC. The possibility of
using this type of micellar compound for imaging lung
pathologies involving water accumulation, which will
depend on the degree of dilution of the imaging agent in
the body relative to its CMC, is worth pursuing in future
studies.
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